Literature DB >> 6362409

Clotrimazole treatment of oral candidiasis in patients with neoplastic disease.

L B Shechtman, L Funaro, T Robin, E J Bottone, J Cuttner.   

Abstract

A double-blind controlled study was performed to evaluate the effectiveness of clotrimazole in the treatment of oral candidiasis in patients with neoplastic disease. Six of seven patients who received clotrimazole had resolution of symptoms and signs of oral candidiasis. In five of six patients who received placebo, clinical progression of signs and symptoms occurred, esophagitis developed, and amphotericin B therapy had to be given. No toxicity was observed that could be attributed to clotrimazole. The results were statistically significant (p = 0.025 by Fisher's exact test). Clotrimazole is effective therapy for oral candidiasis in patients with neoplastic disease, and may prevent the development of esophagitis.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6362409     DOI: 10.1016/0002-9343(84)90755-1

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  6 in total

Review 1.  Interventions for treating oral candidiasis for patients with cancer receiving treatment.

Authors:  Helen V Worthington; Jan E Clarkson; Tasneem Khalid; Stefan Meyer; Martin McCabe
Journal:  Cochrane Database Syst Rev       Date:  2010-07-07

2.  Detection of Candida in concentrated oral rinse cultures by real-time PCR.

Authors:  P Lewis White; David W Williams; Tomoari Kuriyama; Shamim A Samad; Michael A O Lewis; Rosemary A Barnes
Journal:  J Clin Microbiol       Date:  2004-05       Impact factor: 5.948

3.  Optimal management of oropharyngeal and esophageal candidiasis in patients living with HIV infection.

Authors:  Jose A Vazquez
Journal:  HIV AIDS (Auckl)       Date:  2010-04-28

4.  Efficacy of clotrimazole for the management of oral candidiasis: A meta-analysis of randomized clinical trials.

Authors:  Thamer A Almangour; Keith S Kaye; Mohammed Alessa; Khalid Eljaaly; Fadilah Sfouq Aleanizy; Aynaa Alsharidi; Fahad M Al Majid; Naif H Alotaibi; Abdullah A Alzeer; Faris S Alnezary; Abdullah A Alhifany
Journal:  Saudi Pharm J       Date:  2021-03-24       Impact factor: 4.330

5.  Antifungals: need to search for a new molecular target.

Authors:  A T Sangamwar; U D Deshpande; S S Pekamwar
Journal:  Indian J Pharm Sci       Date:  2008 Jul-Aug       Impact factor: 0.975

6.  Role of posaconazole in the management of oropharyngeal and esophageal candidiasis.

Authors:  Jose A Vazquez
Journal:  Ther Clin Risk Manag       Date:  2007-08       Impact factor: 2.423

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.